May 3, 2016—Genentech is offering 340B providers refunds for charges above statutorily defined ceiling prices on 25 products sold from the first quarter of 2012 to the second quarter of 2013. [ms-protect-content id=”2799″]
The biopharmaceutical company announced the repayments in a public notice on the federal 340B drug pricing program homepage. Genentech owes providers money because it recalculated its average manufacturer prices and best prices for the products for the 18-month period. Those new values, in turn, required Genentech to lower it 340B ceiling prices for the products for the same period. The 25 affected products are different formulations and package sizes of these 10 medicines:
- Boniva
- Cellcept
- Fuzeon
- Invirase
- Klonopin
- Naprosyn
- Nutropin
- Pegasys
- Xeloda
- Xenical
This is the second time in three years that Genentech has had to give 340B providers refunds on Boniva, Nutropin, and Pegasys due to AMP and best price restatements.
Genentech said it will give entities refunds “where our data indicates a difference between the original and recalculated 340B ceiling price” in an entity’s favor.
If a provider believes it is owed a refund or has questions about the refund process, it should send an email by no later than Dec. 31, 2016 to contractops@gene.com with “Attention: Recalculated 340B Ceiling Prices” in the subject line, Genentech said in the public notice. [/ms-protect-content]